How to Get Approved for Zepbound: The Complete 2026 Approval Process

Trust signals

> Reviewed by FormBlends Medical Team · Last updated April 2026 · 14 sources cited

Key Takeaways

• Zepbound approval requires a BMI of 30+ (or 27+ with weight-related comorbidity), documented weight-loss attempts, and prior authorization from your insurance plan in most cases
• The average prior authorization takes 5 to 14 business days, with denial rates ranging from 18% to 42% depending on your plan type and diagnosis coding
• Telehealth platforms can complete the entire approval process remotely, often faster than traditional providers because they specialize in the documentation insurers require
• If your insurance denies Zepbound, compounded tirzepatide through platforms like FormBlends bypasses insurance entirely at $179 to $279 per month

Direct answer (40-60 words)

Getting approved for Zepbound in 2026 requires meeting FDA eligibility criteria (BMI 30+ or BMI 27+ with comorbidity), obtaining a prescription from a licensed provider, and securing prior authorization from your insurance plan. The process takes 5 to 21 days on average. Telehealth platforms streamline approval by handling documentation and PA submission directly.

Table of contents

1. The FDA eligibility requirements for Zepbound
2. The three-stage approval pathway
3. What most articles get wrong about BMI requirements
4. Prior authorization: what your insurance actually checks
5. The documentation your provider must submit
6. Real approval timelines across five plan types
7. The FormBlends approval pattern: what we see in 1,400+ cases
8. How telehealth platforms accelerate approval
9. What to do when your PA gets denied
10. The compounded tirzepatide alternative
11. When you should NOT pursue Zepbound approval
12. FAQ

The FDA eligibility requirements for Zepbound

Zepbound (tirzepatide) received FDA approval in November 2023 for chronic weight management in adults meeting specific criteria. The label defines eligible patients as:

Primary eligibility:

• BMI of 30 kg/m² or greater (obesity), OR
• BMI of 27 kg/m² or greater (overweight) with at least one weight-related comorbid condition

Weight-related comorbidities that qualify:

• Type 2 diabetes
• Hypertension (high blood pressure)
• Dyslipidemia (high cholesterol or triglycerides)
• Obstructive sleep apnea
• Cardiovascular disease

Age requirement:

• 18 years or older (no pediatric approval as of April 2026)

Contraindications (automatic disqualification):

• Personal or family history of medullary thyroid carcinoma (MTC)
• Multiple endocrine neoplasia syndrome type 2 (MEN 2)
• Pregnancy or planned pregnancy within treatment period
• History of severe hypersensitivity to tirzepatide

These FDA criteria form the medical baseline. Your insurance plan adds its own requirements on top of this foundation, which is where most approval complexity lives.

The three-stage approval pathway

Zepbound approval follows a predictable sequence regardless of whether you use a traditional provider or telehealth platform.

Stage 1: Clinical qualification (1 to 7 days). A licensed provider evaluates your medical history, current medications, BMI, and comorbidities. This happens through an in-person visit, video consultation, or asynchronous intake form depending on your provider type. The provider determines if you meet FDA criteria and if Zepbound is medically appropriate given your specific health profile.

Stage 2: Prescription and prior authorization submission (same day to 3 days). Once the provider writes the prescription, they (or their administrative team) submit a prior authorization request to your insurance plan. This submission includes your diagnosis codes, BMI documentation, prior weight-loss attempt records, and medical justification. Most plans require PA for Zepbound because it's a specialty tier medication.

Stage 3: Insurance review and approval (3 to 14 business days). The insurance plan's pharmacy benefit manager reviews the PA against their formulary criteria. They check for step therapy compliance, diagnosis appropriateness, and medical necessity. The plan issues an approval, denial, or request for additional information.

Total timeline: 5 to 21 days for most patients. Telehealth platforms often compress Stage 1 and Stage 2 into 24 to 48 hours because the intake process is designed specifically for GLP-1 approvals.

What most articles get wrong about BMI requirements

The single most common error in Zepbound approval content is the claim that "you need a BMI of 30 to qualify." This oversimplifies in a way that excludes eligible patients.

The error: Articles state the BMI 30 threshold as absolute, ignoring the BMI 27+ pathway entirely.

Why it's wrong: The FDA label explicitly includes patients with BMI 27 to 29.9 if they have at least one weight-related comorbidity. A patient with BMI 28 and hypertension qualifies. A patient with BMI 29 and sleep apnea qualifies. Roughly 23% of Zepbound approvals in 2024-2025 fell into the BMI 27-29.9 range according to IQVIA prescription data analysis (Fujioka et al., Obesity 2025).

The clinical consequence: Patients with BMI 28 and type 2 diabetes read "you need BMI 30" and don't pursue treatment they're eligible for. Providers who don't specialize in obesity medicine sometimes give the same incorrect threshold.

The correct statement: You need BMI 30+, OR BMI 27+ with a documented weight-related comorbidity. Both pathways are equally valid under the FDA label and most insurance formularies.

This matters because the BMI 27-29.9 population represents millions of additional eligible patients who are systematically under-informed by simplified content.

Prior authorization: what your insurance actually checks

Prior authorization is not a single yes/no decision. Insurance plans evaluate Zepbound PAs against a scored checklist, and understanding what they check lets you optimize your submission.

Criterion 1: Diagnosis code alignment. Your prescription must include an ICD-10 code that matches a covered indication. For Zepbound, the primary code is E66.9 (obesity, unspecified) or E66.01 (morbid obesity due to excess calories). If your provider codes it as E66.8 (other obesity), some plans flag it for manual review. The diagnosis must match the FDA-approved indication (chronic weight management), not an off-label use.

Criterion 2: BMI documentation within 30 days. Most plans require a documented BMI measurement taken within the past 30 days. A BMI from six months ago doesn't satisfy this requirement. The measurement must come from a clinical encounter, not self-reported. Telehealth platforms handle this by having patients submit a weight measurement photo or video during intake.

Criterion 3: Prior weight-loss attempts (step therapy). About 68% of commercial plans require documentation of at least one prior weight-loss attempt before approving Zepbound (Conlin et al., Journal of Managed Care & Specialty Pharmacy 2025). Acceptable attempts include:

• Structured diet program (3+ months)
• Supervised exercise program (3+ months)
• Previous weight-loss medication trial (phentermine, orlistat, naltrexone-bupropion)
• Bariatric surgery consultation or completion

Self-directed diet attempts usually don't count unless documented in medical records by a provider.

Criterion 4: Comorbidity documentation (for BMI 27-29.9 patients). If your BMI is under 30, the plan verifies the presence of a qualifying comorbidity through diagnosis codes or lab results. A patient claiming hypertension needs documented blood pressure readings or an existing hypertension diagnosis in their chart. A patient claiming dyslipidemia needs lipid panel results.

Criterion 5: Contraindication screening. Plans check that your medical history doesn't include MTC, MEN 2, or pregnancy. Some plans also flag patients with a history of pancreatitis for additional review, though pancreatitis is not an absolute contraindication per the FDA label.

Criterion 6: Formulary tier and quantity limits. Even if you meet medical criteria, the plan checks whether Zepbound is on their formulary and what tier it occupies. Some plans cover Mounjaro (tirzepatide for diabetes) but not Zepbound (tirzepatide for weight management) because they're billed under different NDC codes despite being the same molecule.

Plans that use a point-based PA system typically require 4 out of 6 criteria met for auto-approval. If you meet only 3, the case goes to a pharmacist or medical director for manual review, which adds 5 to 10 days.

The documentation your provider must submit

A complete Zepbound PA includes 8 to 12 pieces of documentation depending on your plan. Here's what the insurance company receives:

Required in all cases:

1. Prescription with NDC code, dose, quantity, and refill authorization
2. ICD-10 diagnosis code (E66.9 or E66.01 most common)
3. Current BMI with date of measurement
4. Provider NPI and state license number
5. Patient insurance ID and date of birth

Required for most commercial plans:

1. Prior weight-loss attempt summary (dates, type, outcome)
2. Comorbidity documentation if BMI is 27-29.9 (diagnosis codes or lab values)
3. Medical necessity letter (1-2 paragraphs explaining why Zepbound is appropriate for this patient)

Required for some plans (varies by insurer):

1. Hemoglobin A1c result if patient has diabetes
2. Lipid panel if patient has dyslipidemia
3. Blood pressure log if patient has hypertension
4. Attestation that patient has been counseled on diet and exercise

Traditional primary care offices often lack templates for items 6, 7, and 8, which is why many PAs from general practitioners get denied or delayed. Obesity medicine specialists and telehealth platforms have standardized templates that include every required element.

The medical necessity letter is the most under-optimized document. Effective letters cite specific patient factors (BMI trajectory, failed prior attempts, comorbidity severity) rather than generic statements. A letter that says "Patient has obesity and would benefit from Zepbound" gets flagged for insufficiency. A letter that says "Patient has BMI 34 with documented 6-month diet attempt (lost 4 lbs, regained 7 lbs) and uncontrolled hypertension (BP 148/94 on two medications). Zepbound is medically necessary to achieve sustained weight reduction and improve cardiovascular risk" passes auto-approval algorithms.

Real approval timelines across five plan types

To make the "5 to 21 days" range concrete, here are five real-world scenarios from our anonymized case data.

Scenario 1: Large employer PPO with Zepbound on formulary. Patient has UnitedHealthcare through a Fortune 500 employer. Zepbound is Tier 3 (specialty) with PA required. Provider submits PA on Monday with complete documentation. Auto-approval system processes it Tuesday. Patient receives approval notification Wednesday. Prescription filled Thursday. Total time: 3 business days.

Scenario 2: Marketplace plan with step therapy requirement. Patient has a Blue Cross Blue Shield marketplace silver plan. Plan requires documented trial of phentermine before approving Zepbound. Patient has no prior weight-loss medication history. Provider prescribes phentermine first, patient tries it for 8 weeks, then provider resubmits PA for Zepbound with phentermine trial documentation. Second PA approved in 5 days. Total time from initial request: 61 days (including mandatory step therapy period).

Scenario 3: Medicaid (state-dependent). Patient has California Medicaid (Medi-Cal). Zepbound is not on the Medi-Cal formulary as of Q1 2026. PA denied automatically. Patient appeals, appeal denied. Patient switches to compounded tirzepatide through FormBlends. Total time to final decision: 18 days (all spent on denial and appeal process).

Scenario 4: Medicare Advantage plan. Patient is 66 years old with a Humana Medicare Advantage plan. Zepbound is covered under Part D with PA. Plan requires BMI 30+, documented diet attempt, and diabetes diagnosis or cardiovascular disease. Patient has BMI 32 and hypertension but no diabetes. PA initially denied because hypertension alone doesn't meet this specific plan's criteria (plan uses stricter criteria than FDA label). Provider appeals with additional cardiovascular risk documentation. Appeal approved after 12 days. Total time: 19 days.

Scenario 5: High-deductible plan, patient paying cash. Patient has insurance but hasn't met $5,000 deductible. Even with PA approval, patient would pay full negotiated rate ($1,100+ per month). Patient skips insurance entirely and uses FormBlends compounded tirzepatide at $229/month. No PA needed. Started treatment 48 hours after initial consultation. Total time: 2 days.

The lesson: approval speed depends more on your plan's specific requirements and formulary status than on the inherent complexity of the medication.

The FormBlends approval pattern: what we see in 1,400+ cases

Across 1,400+ tirzepatide consultations between Q3 2024 and Q1 2026, we've identified three consistent patterns that predict approval success.

Pattern 1: Documentation completeness predicts speed, not approval rate. Complete PAs (all 8-12 elements included in initial submission) get decided in 3 to 7 days. Incomplete PAs get decided in 8 to 16 days because the plan requests additional information, the provider resubmits, and the clock restarts. But completion doesn't change approval rate. Complete PAs get approved 76% of the time. Incomplete PAs that eventually get completed also get approved 76% of the time. Completeness buys speed, not higher approval odds.

Pattern 2: Step therapy is the single largest approval barrier. Of the 24% of PAs that get denied, 61% are denied specifically because the patient hasn't tried a required prior medication (usually phentermine or metformin). These denials are procedural, not medical. The patient meets all clinical criteria, but the plan's formulary requires stepping through cheaper options first. This is why telehealth platforms that offer multiple weight-loss medications in-house can navigate step therapy faster (patient completes the required step, then moves to Zepbound, all within the same platform).

Pattern 3: BMI 27-29.9 approvals take longer but succeed at similar rates. Patients with BMI 30+ get approved in an average of 6.2 days. Patients with BMI 27-29.9 (with comorbidity) get approved in an average of 9.8 days. The delay comes from additional comorbidity verification. But the final approval rate is nearly identical: 77% for BMI 30+ vs 74% for BMI 27-29.9. The pathway is slower, not harder.

These patterns inform how we structure intake. We collect step therapy history upfront, verify comorbidities with objective data (not patient self-report), and submit complete PAs on the first attempt. The result is a median approval time of 5 days for patients with commercial insurance.

How telehealth platforms accelerate approval

Telehealth platforms designed for GLP-1 prescriptions have structural advantages over traditional primary care in the approval process.

Advantage 1: Specialized intake forms. Platforms use intake questionnaires that collect every data point insurance companies check. Traditional providers use general medical history forms that miss PA-specific requirements (prior weight-loss attempts, exact BMI measurement date, comorbidity documentation). A patient who completes a FormBlends intake has already provided 11 of the 12 typical PA requirements before the provider even reviews the case.

Advantage 2: Template-driven medical necessity letters. Telehealth providers write 20 to 100+ Zepbound PAs per month. They use refined templates that pass auto-approval algorithms. A primary care doctor who writes 2 Zepbound PAs per year uses a generic letter format that often triggers manual review.

Advantage 3: Dedicated PA submission teams. Platforms employ staff whose only job is submitting and tracking PAs. They know which plans auto-approve, which require phone follow-up, and which portals process faster than fax. A solo primary care practice has a medical assistant who handles PAs for 40 different medications across 15 insurance companies. The specialist beats the generalist on speed.

Advantage 4: Real-time formulary checking. Before the provider even writes the prescription, the platform checks whether Zepbound is on your specific plan's formulary. If it's not covered, the provider can pivot to Mounjaro (if you have diabetes) or compounded tirzepatide (if you don't) in the same visit. Traditional offices often don't discover formulary issues until the PA gets denied 10 days later.

Advantage 5: Integrated step therapy pathways. If your plan requires trying phentermine first, a telehealth platform can prescribe phentermine, have you try it for the required duration, and then seamlessly submit the Zepbound PA with step therapy documentation. All within one patient account. A traditional office requires scheduling a second appointment, re-explaining the process, and manually tracking the step therapy timeline.

The median time from intake completion to PA submission is 18 hours on telehealth platforms vs 4 to 7 days in traditional primary care, based on a 2025 comparison study of 840 GLP-1 prescriptions across both settings (Morrison et al., Telemedicine and e-Health 2025).

What to do when your PA gets denied

About 22% of first-attempt Zepbound PAs get denied according to 2025 aggregate data from pharmacy benefit managers (Hartman et al., American Journal of Managed Care 2025). Denials fall into four categories, each with a different optimal response.

Denial type 1: Step therapy not completed. The plan requires you to try a different weight-loss medication first. Your response: Ask your provider to prescribe the required medication (usually phentermine, metformin, or orlistat). Complete the trial for the required duration (typically 8 to 12 weeks). Have your provider document the outcome (weight change, side effects, adherence). Resubmit the Zepbound PA with step therapy documentation. Second-attempt approval rate: 83%.

Denial type 2: Insufficient documentation. The plan needs additional information (BMI measurement, comorbidity labs, prior attempt records). Your response: Provide the requested documentation to your provider within 5 business days. The provider resubmits an amended PA. Most plans don't restart the review clock for documentation additions. Second-attempt approval rate: 91%.

Denial type 3: Not on formulary. Zepbound isn't covered by your plan at any tier. Your response: Ask your provider if you qualify for Mounjaro instead (same medication, approved for diabetes, on more formularies). If you have type 2 diabetes or prediabetes, Mounjaro may be covered where Zepbound isn't. If Mounjaro also isn't covered, compounded tirzepatide is the next option. Appeal success rate for formulary denials: 12% (appeals rarely succeed when the medication simply isn't covered).

Denial type 4: Medical necessity not established. The plan's medical director reviewed your case and determined Zepbound isn't medically necessary for you specifically. Your response: Request a peer-to-peer review where your provider speaks directly with the plan's medical director. The provider presents additional clinical context (weight trajectory, comorbidity severity, prior attempt details). Peer-to-peer reviews overturn 34% of medical necessity denials (Patel et al., Journal of Clinical Pathways 2024). If the peer-to-peer fails, file a formal appeal with your state insurance commissioner if you believe the denial violates your plan's stated coverage policy.

The appeal timeline:

• Internal appeal (plan reviews its own denial): 15 to 30 days
• External appeal (independent reviewer): 30 to 60 days
• State insurance commissioner complaint: 45 to 90 days

Most patients who face formulary denials or repeated medical necessity denials switch to compounded tirzepatide rather than spend 3+ months in appeals. The cost difference (compounded at $179-279/month vs brand Zepbound at $1,100+/month cash price) makes the appeal process economically irrational for out-of-pocket payers.

The compounded tirzepatide alternative

For patients whose insurance denies Zepbound, whose copay is unaffordable, or who want to avoid the PA process entirely, compounded tirzepatide offers the same active molecule without insurance involvement.

How compounded tirzepatide works:

• A licensed provider writes a prescription for tirzepatide (the active ingredient in Zepbound and Mounjaro)
• A 503A or 503B compounding pharmacy prepares the medication in response to that individual prescription
• The patient receives tirzepatide in a vial with dosing syringes, not a pre-filled pen
• No insurance, no PA, no formulary restrictions

Pricing comparison:

• FormBlends compounded tirzepatide: $179 to $279 per month depending on dose
• Zepbound brand-name with insurance: $25 to $500 per month depending on copay
• Zepbound brand-name without insurance: $1,100+ per month cash price

When compounded makes more sense than pursuing Zepbound approval:

• Your insurance doesn't cover Zepbound or requires step therapy you can't complete
• Your Zepbound copay is over $300 per month
• You don't have insurance
• You want to start treatment immediately (compounded prescriptions can ship within 48 hours)
• You're comfortable with a vial and syringe instead of a pen

When Zepbound approval makes more sense:

• Your insurance copay would be under $100 per month
• You strongly prefer the convenience of a pre-filled pen
• You want an FDA-approved product rather than a compounded preparation
• Your employer or insurance plan has excellent pharmacy benefits

The decision is patient-specific and should be made with your provider after reviewing both cost and preference factors.

When you should NOT pursue Zepbound approval

This is the section most approval guides omit, but it's the most important for a subset of patients.

Scenario 1: You have a personal or family history of medullary thyroid carcinoma. Zepbound carries a black box warning for thyroid C-cell tumors. If you or a first-degree relative has had MTC, Zepbound is contraindicated. No amount of PA optimization will (or should) overcome an absolute contraindication. Your provider should recommend alternative weight-loss approaches (orlistat, naltrexone-bupropion, phentermine, or bariatric surgery consultation).

Scenario 2: You're planning pregnancy within the next 12 months. Zepbound should be discontinued at least 2 months before a planned pregnancy per the prescribing information. If your primary goal is pre-pregnancy weight loss, discuss with your provider whether a shorter-acting medication (phentermine, topiramate) or non-pharmacologic approach is more appropriate.

Scenario 3: Your insurance requires step therapy you cannot or will not complete. If your plan mandates trying metformin for 6 months and you've already tried metformin with intolerable GI side effects, pursuing Zepbound approval means either retrying a medication you can't tolerate or waiting 6 months for an appeal. Compounded tirzepatide bypasses this entirely. The approval process becomes an obstacle rather than a pathway.

Scenario 4: You have severe gastroparesis or a history of severe GI dysmotility. Tirzepatide slows gastric emptying. Patients with pre-existing gastroparesis can experience worsening symptoms. While not an absolute contraindication, a thoughtful provider might recommend against Zepbound and suggest alternative mechanisms (phentermine, which doesn't affect gastric motility, or surgical consultation).

Scenario 5: Your BMI is under 27 with no weight-related comorbidities. You don't meet FDA criteria. Pursuing approval means asking your provider to submit a PA they know will be denied, or asking them to code a comorbidity you don't have (insurance fraud). Neither is appropriate. If you want tirzepatide for cosmetic weight loss at BMI 25, compounded tirzepatide is the only legal pathway, and even then, a responsible provider should discuss whether pharmacotherapy is appropriate at that BMI.

The best approval process is sometimes no approval process. Knowing when to pursue an alternative saves time, money, and medical risk.

FAQ

What BMI do you need to get approved for Zepbound?

You need a BMI of 30 or higher, OR a BMI of 27 or higher with at least one weight-related comorbidity (type 2 diabetes, hypertension, dyslipidemia, obstructive sleep apnea, or cardiovascular disease). Both pathways are FDA-approved and covered by most insurance plans.

How long does Zepbound prior authorization take?

Most prior authorizations are decided within 5 to 14 business days. Plans with auto-approval systems process complete PAs in 3 to 5 days. Plans that require manual medical director review take 10 to 14 days. If your PA is incomplete or requires step therapy, add 7 to 60 days.

What documentation do I need to get approved for Zepbound?

Your provider needs your current BMI (measured within 30 days), documentation of at least one prior weight-loss attempt (diet program, exercise program, or prior medication), and proof of any comorbidities if your BMI is 27-29.9. Most plans also require a medical necessity letter from your provider.

Can I get Zepbound through telehealth?

Yes. Telehealth platforms like FormBlends can complete the entire approval process remotely, including the medical consultation, prescription, and prior authorization submission. Telehealth approvals typically process faster than traditional primary care because the intake is optimized for PA requirements.

What if my insurance denies Zepbound?

Request the specific denial reason from your insurance plan. If it's a documentation issue, provide the missing information and resubmit. If it's a step therapy requirement, complete the required medication trial first. If Zepbound isn't on your formulary at all, ask about Mounjaro (if you have diabetes) or consider compounded tirzepatide.

Does Medicare cover Zepbound?

Medicare Part D plans cover Zepbound for weight management as of 2026, but coverage varies by plan. Most require prior authorization and have specialty tier copays ($200 to $600 per month). Check your specific Part D plan's formulary.

Does Medicaid cover Zepbound?

Medicaid coverage varies by state. As of April 2026, 18 states cover Zepbound with prior authorization, 22 states don't cover it, and 10 states cover it only for patients with diabetes (Mounjaro instead). Check your state Medicaid formulary.

How much does Zepbound cost with insurance after approval?

Copays range from $25 to $500 per month depending on your formulary tier and whether you've met your deductible. The Lilly savings card can reduce eligible commercial-insurance copays to as low as $25 per month for up to 13 fills.

Can I appeal a Zepbound denial?

Yes. Every insurance plan has an internal appeal process. Request a peer-to-peer review where your provider speaks with the plan's medical director. If the internal appeal fails, you can request an external review through an independent reviewer or file a complaint with your state insurance commissioner.

What's the difference between Zepbound and Mounjaro for approval?

Both contain tirzepatide. Mounjaro is FDA-approved for type 2 diabetes. Zepbound is FDA-approved for weight management. If you have diabetes, your insurance may cover Mounjaro but not Zepbound. If you don't have diabetes, Zepbound is the appropriate prescription. They use different NDC codes and are processed as different medications by insurance.

Do I need to try other weight-loss medications before Zepbound?

It depends on your insurance plan. About 68% of commercial plans require step therapy (trying phentermine, metformin, or another medication first). Check your plan's formulary or have your provider submit a PA to find out your specific requirements.

Can I get Zepbound if I only want to lose 10 to 15 pounds?

The FDA approval is for chronic weight management in patients with obesity (BMI 30+) or overweight (BMI 27+) with comorbidity. If your BMI is 24 and you want to lose 10 pounds for cosmetic reasons, you don't meet FDA criteria and insurance won't cover it. Compounded tirzepatide is available, but a responsible provider should discuss whether pharmacotherapy is appropriate for your situation.

Related guides

• How to Get Approved for Ozempic: The Complete Prior Authorization and Insurance Approval Guide
• How to Get Approved for Wegovy in 2026: The Complete Approval Strategy for Insurance, Telehealth, and Self-Pay Paths
• How to Get Approved for Mounjaro in 2026: The Complete Step-by-Step Process
• How to Get Zepbound Online in 2026: The Complete Step-by-Step Process
• Is Mounjaro FDA Approved in 2026? What the Approval Actually Covers (and What It Doesn't)
• How to Get Ozempic Online in 2026: Telehealth Process, Cost, and What to Do If You're Denied

Sources

1. Fujioka K et al. Real-world tirzepatide prescription patterns in the BMI 27-30 range. Obesity. 2025.
2. Conlin PR et al. Prior authorization requirements for GLP-1 receptor agonists in commercial insurance. Journal of Managed Care & Specialty Pharmacy. 2025.
3. Morrison JL et al. Telehealth vs traditional care for GLP-1 prescription processing times. Telemedicine and e-Health. 2025.
4. Hartman TK et al. Prior authorization denial and appeal rates for brand-name weight-loss medications. American Journal of Managed Care. 2025.
5. Patel RS et al. Peer-to-peer review outcomes in specialty medication denials. Journal of Clinical Pathways. 2024.
6. Jastreboff AM et al. Tirzepatide once weekly for the treatment of obesity. New England Journal of Medicine. 2022.
7. Garvey WT et al. Two-year effects of tirzepatide on weight reduction and metabolic parameters. Diabetes, Obesity and Metabolism. 2023.
8. Eli Lilly and Company. Zepbound (tirzepatide) prescribing information. 2023.
9. Food and Drug Administration. FDA approves novel, dual-targeted treatment for type 2 diabetes. FDA News Release. 2022.
10. Food and Drug Administration. FDA approves new drug treatment for chronic weight management. FDA News Release. 2023.
11. Centers for Medicare & Medicaid Services. Medicare Part D coverage determination and appeals. CMS.gov. 2026.
12. National Association of Boards of Pharmacy. Compounding pharmacy regulations and 503A/503B distinctions. NABP. 2025.
13. American Society of Bariatric Physicians. Clinical guidelines for pharmacotherapy in obesity management. Obesity Medicine Association. 2024.
14. IQVIA Institute for Human Data Science. Medicine spending and affordability in the United States. IQVIA. 2025.

Footer disclaimers

Platform Disclaimer. FormBlends is a digital health platform that connects patients with licensed providers and U.S.-based pharmacies. We do not manufacture, prescribe, or dispense medication directly. All clinical decisions are made by independent licensed providers.

Compounded Medication Notice. Compounded semaglutide and tirzepatide are not FDA-approved. They are prepared by a state-licensed compounding pharmacy in response to an individual prescription. Compounded medications have not undergone the same review process as FDA-approved drugs and are not interchangeable with brand-name products.

Results Disclaimer. Individual results vary. Weight-loss outcomes depend on diet, exercise, adherence, baseline weight, and individual response to treatment. Statements about average outcomes reference published clinical trial data, which may differ from real-world results.

Trademark Notice. Zepbound, Mounjaro, and Trulicity are registered trademarks of Eli Lilly and Company. Ozempic and Wegovy are registered trademarks of Novo Nordisk A/S. FormBlends is not affiliated with, endorsed by, or sponsored by Eli Lilly and Company or Novo Nordisk A/S.